Inovio Pharmaceuticals reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.
Browsing: proactive
ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.
OXiGENE shares rose in pre-market trading Monday
Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.
ImmunoCellular Therapeutics will present positive results from a phase 1 clinical study on its ICT-107 therapy, a treatment for a type of brain tumor.